Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
EARLY_PHASE1
1–21
10 sites in CO, DC, IL +6
What this study is about
This EARLY_Phase 1 study is testing Lorlatinib in people with anaplastic astrocytoma. The primary outcome being measured is Disease Control Rate.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
lorlatinib, ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
oral
Primary: Disease Control Rate, Number of participants with lorlatinib-related adverse events as assessed by CTCAE v5.0
Secondary: Associations between genomic tumor alterations with radiographic response, Objective Response Rate (ORR) in HGG, Overall Survival (OS) in HGG, Progression-Free Survival in HGG
Oncology